PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy

Martina Vrankar (Avtor), Matjaž Zwitter (Avtor), Izidor Kern (Avtor), Karmen Stanič (Avtor)

Povzetek

The standard treatment for inoperable locally advanced non-small cell lung cancer (LA NSCLC) includes concurrent or sequential chemotherapy (ChT) and radiation therapy (RT). Long term survival rates with these approaches remains only in the order of 15%, therefore new treatment strategies, including immunotherapy, are under investigation, with programmed death ligand-1 (PD-L1) as one of the major players. We evaluated the clinical significance of PD-L1 expression in tumor samples from patients with inoperable LA NSCLC who underwent concurrent chemoradiotherapy (CRT) in our institution between 2005 and 2010 and correlated their expression with clinicopathological parameters and outcome of treatment. Among 107 patients treated with concurrent CRT, a total of 43 (36 males and 7 females) had sufficient tissue for immunohistochemical (IHC) staining. The expression of PD-L1 was demonstrated in 7 tumors, in 6 males and 1 female. No statistical significant differences in patient characteristics, including age, smoking status and gender, were found according to the PD-L1 expression. After a median follow up of 103.6 months, median progression free survival (PFS) was 19.9 months in patients without and 10.1 months in patients with PD-L1 expression (p=0.008). Median overall survival (OS) was 28.4 and 12.1 months for PD-L1 negative and PD-L1 positive patients, respectively (p=0.012). In conclusions, patients with PD-L1 expression had shorter PFS and OS after concurrent CRT in LA NSCLC. Unfortunately, only small number of patients had tissue available for the IHC testing, therefore no firm conclusions could be made and further investigation is warranted.

Ključne besede

nedrobnocelični rak;pljučni rak;kemoradioterapija;preživetje;non-small cell lung cancer;lung cancer;chemoradiotherapy;survival;

Podatki

Jezik:	Angleški jezik
Leto izida:	2018
Tipologija:	1.01 - Izvirni znanstveni članek
Organizacija:	OI - Onkološki inštitut Ljubljana
Založnik:	AEPress
UDK:	616.2
COBISS:	2806907
ISSN:	0028-2685
Št. ogledov:	817
Št. prenosov:	216
Ocena:	0 (0 glasov)
Metapodatki:

Ostali podatki

Sekundarne ključne besede:	nedrobnocelični rak;pljučni rak;kemoradioterapija;preživetje;
Strani:	str. 140-146
Letnik:	ǂVol. ǂ65
Zvezek:	ǂno. ǂ1
Čas izdaje:	2018
DOI:	10.4149/neo_2018_170206N77
ID:	12272742